A weakly positive human papillomavirus hybrid capture ii result correlates with a significantly lower risk of cervical intraepithelial neoplasia 2,3 after atypical squamous cells of undetermined significance cytology

Journal of Lower Genital Tract Disease

Volumn 14, Issue 3, 2010, Pages 174-178

  Jarboe, Elke A ^a   Venkat, Pavithra ^a   Hirsch, Michelle S ^a   Cibas, Edmund S ^a   Crum, Christopher P ^a   Garner, Elizabeth I O ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ASCUS; cervical intraepithelial neoplasia; high risk human papillomavirus; Hybrid CaptureII

Indexed keywords

ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; BIOASSAY; CHEMOLUMINESCENCE; COLPOSCOPY; CURETTAGE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYBRID CAPTURE II ASSAY; MAJOR CLINICAL STUDY; MEASUREMENT; NUCLEIC ACID HYBRIDIZATION; PREVALENCE; QUALITATIVE ANALYSIS; RELATIVE LIGHT UNIT; RISK; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOCHEMISTRY; EARLY DIAGNOSIS; MOLECULAR DIAGNOSIS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; UTERINE CERVIX; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; EARLY DETECTION OF CANCER; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK ASSESSMENT;

EID: 77954905443     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/LGT.0b013e3181cd6d4b     Document Type: Article

References (21)

1. Castle PE, Lorincz AT, Mielzynska-Lohnas I, Scott DR, Glass AG, Sherman ME, et al. Results of human papillomavirus DNA testing with the Hybrid Capture 2 assay are reproducible. J Clin Microbiol 2002;40:1088-90.
2. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007;11:201-22.
3. Santos AL, Derchain SF, Martins MR, Sarian LO, Martinez EZ, Syrjanen KJ. Human papillomavirus viral load in predicting high-grade CIN in women with cervical smears showing only atypical squamous cells or low-grade squamous intraepithelial lesion. Sao Paulo Med J 2003;121:238-43.
4. Crum CP. Symposium part 1: Should the Bethesda System terminology be used in diagnostic surgical pathology?: Point. Int J Gynecol Pathol 2003;22:5-12.
5. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
6. Crum CP, Beach KJ, Hedley ML, Yuan L, Lee KR, Wright TC, et al. Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol. J Infect Dis 2004;189:1348-54.
7. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-293.
8. Xu Y, Dotto J, Hui Y, Lawton K, Schofield K, Hui P. High grade cervical intraepithelial neoplasia and viral load of high-risk human papillomavirus: significant correlations in patients of 22 years old or younger. Int J Clin Exp Pathol 2009;2:169-175.
9. Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002;360:228-9.
10. Tsai HT, Wu CH, Lai HL, Li RN, Tung YC, Chuang HY, et al. Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiol Biomarkers Prev 2005;14: 2544-9.
11. Sherman ME, Wang SS, Wheeler CM, Rich L, Gravitt PE, Tarone R, et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003;12:1038-44.
12. de Cremoux P, Coste J, Sastre-Garau X, Thioux M, Bouillac C, Labbe S, et al. Efficiency of the Hybrid Capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology. Am J Clin Pathol 2003; 120:492-9.
13. Federschneider JM, Yuan L, Brodsky J, Breslin G, Betensky RA, Crum CP. The borderline or weakly positive Hybrid Capture II HPV test: a statistical and comparative (PCR) analysis. Am J Obstet Gynecol 2004;191:757-61.
14. Knoepp SM, Kuebler DL, Wilbur DC. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases. Diagn Mol Pathol 2007;16:125-9.
15. Ordi J, Alonso I, Torne A, Esteve R, Sierra E, Campo E, et al. Human papillomavirus load in Hybrid Capture II assay: does increasing the cutoff improve the test? Gynecol Oncol 2005;99:313-9.
16. Castle PE, Schiffman M, Wheeler CM. Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. Am J Obstet Gynecol 2004;191:1590-7.
17. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, et al. HPV testing in primary screening of older women. Br J Cancer 1999;81:554-8.
18. Guyot A, Karim S, Kyi MS, Fox J. Evaluation of adjunctive HPV testing by Hybrid Capture II in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy. BMC Infect Dis 2003;3:23.
19. Kulmala SM, Syrjanen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, et al. Human papillomavirus testing with the Hybrid Capture 2 assay and PCR as screening tools. J Clin Microbiol 2004;42:2470-5.
20. Seme K, Fujs K, Kocjan BJ, Poljak M. Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA test using polymerase chain reaction and genotyping. J Virol Methods 2006;134:252-6.
21. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.